Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunicum AB (DE:1YG0)
FRANKFURT:1YG0
Holding DE:1YG0?
Track your performance easily
1YG0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.26 - €1.37
Previous Close€0.78
Volume0.00
Average Volume (3M)N/A
Market Cap
€40.05M
Enterprise Value€37.55M
Total Cash (Recent Filing)kr55.40M
Total Debt (Recent Filing)kr26.49M
Price to Earnings (P/E)―
Beta-1.92
Next Earnings
Feb 13, 2025EPS Estimate
-€0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)198.08
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
1YG0 FAQ
What was Immunicum AB’s price range in the past 12 months?
Immunicum AB lowest stock price was €0.26 and its highest was €1.37 in the past 12 months.
What is Immunicum AB’s market cap?
Currently, no data Available
When is Immunicum AB’s upcoming earnings report date?
Immunicum AB’s upcoming earnings report date is Feb 13, 2025 which is in 83 days.
How were Immunicum AB’s earnings last quarter?
Immunicum AB released its earnings results on Nov 08, 2024. The company reported -€0.04 earnings per share for the quarter, beating the consensus estimate of -€0.06 by €0.021.
Is Immunicum AB overvalued?
According to Wall Street analysts Immunicum AB’s price is currently Overvalued.
Does Immunicum AB pay dividends?
Immunicum AB does not currently pay dividends.
What is Immunicum AB’s EPS estimate?
Immunicum AB’s EPS estimate is -€0.06.
How many shares outstanding does Immunicum AB have?
Immunicum AB has 50,359,577 shares outstanding.
What happened to Immunicum AB’s price movement after its last earnings report?
Immunicum AB reported an EPS of -€0.04 in its last earnings report, beating expectations of -€0.06. Following the earnings report the stock price went up 3.571%.
Which hedge fund is a major shareholder of Immunicum AB?
Currently, no hedge funds are holding shares in DE:1YG0
---
Immunicum AB Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-19.32%
Trailing 12-Months
Asset Growth
-9.38%
Trailing 12-Months
Company Description
Immunicum AB
Immunicum AB is a biopharmaceutical company. It develops immune therapies against a range of solid tumors. The company's lead product, ilixadencel, has been developed to be able to take advantage of each patient's own tumor antigen. Immunicum's business currently consists of research and development for the production of pharmaceuticals.
---
Technical Analysis
---